ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, w

Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn., Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE:SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creating durable, accurately shaped, stain resistant attachments. "With the l

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai

ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w

ST. PAUL, Minn., Oct. 14, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), formerly 3M Health Care, today pledges to use 100% renewable electricity across its worldwide operations by 2030. This move highlights Solventum's commitment to sustainability and the critical role of the healthcare industry in addressing climate change. It also demonstrates how the company is integrating sustainable practices in its facilities and innovating solutions for customers. Since 2021, Solventum has transitioned ten manufacturing sites across the United States, Canada, Germany, Poland and France to

ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

New V.A.C.® Peel and Place Dressing makes negative pressure wound therapy more accessible, less painful ST. PAUL, Minn., Sept. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the launch of the V.A.C.® Peel and Place Dressing, an integrated dressing and drape that can be applied in less than two minutesi and worn by patients for up to seven daysii. Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be

ST. PAUL, Minn., Aug. 28, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) executives plan to participate in the following investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Wednesday, September 4, 2024 at 11:00 a.m. ET.Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at 11:30 a.m. ET.Live and archived audio webcasts will be available on the company's website at investors.solventum.com.    About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a

ST. PAUL, Minn., Aug. 20, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), formerly 3M Health Care, today announced that its autonomous coding solution has received Toolbox designation from Epic in the Fully Autonomous Coding category. Toolbox is a designation for products using established integration technologies in specific categories that meet Epic's recommended connection pattern. Solventum's ambient clinical documentation solution can be found in the Connection Hub on Epic Showroom. By connecting workflows between clinicians and coders, this integrated approach enables comple

Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by

UPS: -9% | United Parcel Service Q2 2024 Adj EPS $1.79 Misses $1.99 Estimate, Sales $21.820B Miss $22.183B Estimate SOLV: 6.9% | Solventum shares are trading higher following a report suggesting Trian has built a stake in the company. TUSK:  57% | Mammoth Energy Services shares are trading higher after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.

- Bloomberg

5 analysts have shared their evaluations of Solventum (NYSE:SOLV) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 0 2 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 1 2M Ago 0 0 0 0 1 3M Ago 0 0 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $57.4, a high estimate of $70.00, and a low estimate of $48.00. Experiencing a 11.24% decline, the current averag

Morgan Stanley analyst Patrick Wood maintains Solventum (NYSE:SOLV) with a Equal-Weight and lowers the price target from $70 to $55.

Goldman Sachs analyst David Roman maintains Solventum (NYSE:SOLV) with a Sell and lowers the price target from $54 to $48.

Ratings for Solventum (NYSE:SOLV) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 1 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 1 2M Ago 0 0 1 0 0 3M Ago 0 0 2 0 0 Analysts have recently evaluated Solventum and provided 12-month price targets. The average target is $64.6, accompanied by a high estimate of $70.00 and a low estimate of $54.00. This current average represents a 7.

B of A Securities analyst Travis Steed maintains Solventum (NYSE:SOLV) with a Neutral and lowers the price target from $70 to $60.

Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00

Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00

Wolfe Research initiated coverage of Solventum Corporation with a rating of Peer Perform

BTIG Research initiated coverage of Solventum Corporation with a rating of Neutral

Argus initiated coverage of Solventum Corporation with a rating of Hold

Goldman initiated coverage of Solventum Corporation with a rating of Sell and set a new price target of $54.00

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

4 - Solventum Corp (0001964738) (Issuer)

SC 13G/A - Solventum Corp (0001964738) (Subject)

SC 13G/A - Solventum Corp (0001964738) (Subject)

S-4 - Solventum Corp (0001964738) (Filer)

SCHEDULE 13G - Solventum Corp (0001964738) (Subject)

IRANNOTICE - Solventum Corp (0001964738) (Filer)

10-Q - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

IRANNOTICE - Solventum Corp (0001964738) (Filer)

10-Q - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai

ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w

Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by

ST. PAUL, Minn., July 16, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter 2024 financial results on Thursday, August 8, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its second quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275. A replay of the w

ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi